ReviewFrontiers in immunology2013
Mesenchymal stem cells in tissue repair.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 206 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Single Center, Open Label, Single Dose, Dose Escalation Study Assessing the Safety and Tolerability of AllogeneiC MEsenchymAl Stem CEll Infusion in Adults With Cystic Fibrosis-CEASE CF
A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease
Who cites it
206 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Adipose-derived stem cell therapies for complex anal fistula: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Pooled it
- Pooled it
- Adjuvant Biological Therapies in Chronic Leg Ulcers.International journal of molecular sciences · 2017Pooled it
- Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation.World journal of methodology · 2025Trial
- Article
- Review
- The osteochondral regeneration paradox: why biomimetic scaffolds are biologically superior but injectable systems dominate the clinic.RSC advances · 2026Review
- Article
- Oncological Safety of High Hydrostatic Pressure Treatment: Effects on Cancer-Associated Fibroblast-like Transdifferentiation of Adipose Stromal Cells.Current issues in molecular biology · 2026Article
- Evaluation of differentiation of the umbilical cord blood-derived mesenchymal stem cells into male germ-line cells in two-dimensional and three-dimensional scaffolds containing naringin.Iranian journal of basic medical sciences · 2026Article
- Immunomodulatory Delivery Materials for Tissue Repair.Advanced healthcare materials · 2025Review
- Current Status of Stromal Vascular Fraction from Adipose Tissue in the Clinical Application for Osteoarthritis Treatment.Tissue engineering and regenerative medicine · 2025Review
- RIG-I-driven CDKN1A stabilization reinforces cellular senescence.Science China. Life sciences · 2025Article
- Enhanced reno-protective effects of CHIR99021 modified mesenchymal stem cells against rat acute kidney injury model.BioImpacts : BI · 2025Article
- Mesenchymal Stem Cells in Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence.Frontiers in bioengineering and biotechnology · 2025Review
- Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity.Frontiers in immunology · 2025Article
- Potential Mechanism and Perspectives of Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Review.Global medical genetics · 2024Review
- Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.International journal of surgery (London, England) · 2024Review
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The advent of mesenchymal stem cell (MSC)-based therapies for clinical therapeutics has been an exciting and new innovation for the treatment of a variety of diseases associated with inflammation, tissue damage, and subsequent regeneration and repair. Application-based ability to measure MSC potency and fate of the cells post-MSC therapy are the variables that confound the use of MSCs therapeutics in human diseases. An evaluation of MSC function and applications with attention to detail in the preparation as well as quality control and quality assurance are only as good as the assays that are developed. In vivo measures of efficacy and potency require an appreciation of the overall pathophysiology of the model and standardization of outcome measures. The new concepts of how MSC's participate in the tissue regeneration and wound repair process and further, how this is impacted by estimates of efficacy and potency are important new topics. In this regard, this chapter will review some of the in vitro and in vivo assays for MSC function and activity and their application to the clinical arena.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.